Epic Sciences

Select Publications

07.05.2018

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

Autio KA, Dreicer R, Anderson J, et al. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncology. Advance Online Publication 2018 July. DOI:10.1001/jamaoncol.2018.2168

06.28.2018

Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer

Scher HI, Graf RP, Schreiber NA, et al. Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncology. Advance Online Publication: 2018 June. DOI:10.1001/jamaoncol.2018.1621

06.19.2018

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

Boudadi, K, Antonarakis, ES, et al. Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 9(47). DOI:10.18632/oncotarget.25564

04.26.2017

Cellular expression of PD-L1 in the peripheral blood of lung cancer patients is associated with worse survival.

Boffa, D et al. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. 2017 January. DOI: 10.1158/1055-9965.EPI-17-0120

11.24.2016

Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer.

Scher, H et al. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. 2016 November. DOI:/10.1016/j.eururo.2016.11.024

09.22.2016

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.

Anantharaman, A et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer 201616:744 DOI: 10.1186/s12885-016-2758-3

09.18.2016

Phenotypic diversity of circulating tumor cells in patients with metastatic castration-resistant prostate cancer.

McDaniel AS, et al. Phenotypic diversity of circulating tumor cells in patients with metastatic castration-resistant prostate cancer. BJU Int. 2016 Aug . doi: 10.1111/bju.13631. [Epub ahead of print]